News Center

Read the latest news from Jasper Therapeutics

September 22, 2020 Jasper Therapeutics Doses First Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent for Patients with Myelodysplastic Syndromes/Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation
August 12, 2020 Jasper Therapeutics Strengthens Management Team with Appointment of Biopharma Industry Executive Kevin N. Heller, M.D., as Executive Vice President, Research and Development
January 9, 2020 Jasper Therapeutics Expands Series A Bringing Total Corporate Funding to More Than $50 Million
December 9, 2019 Jasper Therapeutics Announces Upcoming Data on JSP191 at 61st American Society of Hematology
December 6, 2019 Jasper Therapeutics Launches with $35 Million Series A Financing